Medtronic plc (MDT) Stock: Price, Forecast & Analyst Target
Medtronic plc (MDT) — MoonshotScore 80/100 (Exceptional band), calculated Oct 4, 2026. Price $86.38 (-0.07%), as of the Oct 2, 2026 trading session; market cap $111B. Expected results Nov 17, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 12.59× (market value Oct 2, 2026; cash Jul 31, 2026) · expected results Nov 17, 2026
Medtronic plc · MDT · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-12: Medtronic sells device-based therapies spanning cardiovascular care, surgery, neuroscience, and diabetes, with revenue tied to procedures, implanted systems, clinical platforms, monitoring, and recurring consumables. The case now depends on whether expanding sales can produce durable operating leverage without gross-profit pressure or uneven cash conversion weakening the result.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Medtronic (MDT)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, though the balance sheet is only middling. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $9.76B (Q1 FY2027, quarter ended Jul 2026)
- EPS beat 6 of 8
- Altman Z 2.88 · Piotroski F 9
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 79 | Strong | |
| 80 | Strong | |
| 80 | Strong | |
| 80 | Strong | |
| 80 | Exceptional | |
| 80 | Exceptional |
The score was 80 in the stored Oct 3, 2026 snapshot and remains 80 in the current publication computed Oct 4, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $86.38 | |
| Change on the day | -0.07% | |
| 52-week range | $73.31–$106.33 | |
| Market capitalisation | $111B | |
| Price / earnings (trailing) | 21.14 | |
| Shares traded on the day | 34.60M | |
| Beta (volatility vs the S&P 500) | 0.57 | |
| Dividends per share (last 12 months) | $2.86 | |
| Dividend yield (last 12 months) | 3.31% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Taken together, we expect fiscal year '27 operating profit to grow approximately 10%, with operating margin expanding approximately 50 basis points year-over-year.
Thierry Pieton · Statement from
And on the full year, we're going to deliver a leverage P&L.
Thierry Pieton · Statement from
Chronological order, not a duration scale. Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Medtronic (MDT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the MDT film — every key number, told as a short cinematic story
~2 min · open the film
What is Medtronic (MDT), and what does it report?
Short answer · as of
Medtronic plc is more than a conventional medical-device manufacturer.
Research dated 2026-09-12.
Medtronic plc is more than a conventional medical-device manufacturer. Its portfolio reaches from pacemakers, defibrillators, valves, and stent grafts to surgical instruments, robotic guidance, imaging, ventilation, insulin pumps, glucose monitoring, and the consumables and software attached to those therapies.
Reported revenue therefore measures a blend of implant demand, procedure activity, equipment and instrument use, patient monitoring, and recurring diabetes supplies. Cardiovascular contributes the largest segment base, followed by neuroscience and medical surgical, while diabetes is smaller but carries a distinct consumables component.
The income statement reflects the combined portfolio rather than a uniform product cycle. Annual revenue and net income have advanced recently, while quarterly profit and cash flow still fluctuate enough to make operating leverage more informative than sales growth alone.
What do the latest results show for Medtronic (MDT)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $9.76B.
Research dated 2026-09-12.
The latest quarter extended year-over-year revenue growth even as sales eased from the immediately preceding period. Operating profit, net income, and diluted earnings improved against the preceding quarter and year-earlier period, but gross profit retreated sequentially, leaving a stronger bottom line without uniform improvement across the statement.
Reported revenue and adjusted earnings cleared consensus, continuing a pattern of adjusted earnings finishing above expectations. That record shows dependable execution against forecasts, while the gross-profit and operating-cash-flow series show why headline beats alone do not establish improving economics.
Management has committed to operating-profit growth and margin expansion and describes the full-year model as leveraged. That is a forward commitment rather than an explanation for the latest change, and it will be tested by the relationship among revenue, gross profit, operating expenses, and cash generation.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $9.76B Jul 31, 2026
- Latest quarter · R&D
- $771.00M Jul 31, 2026
- Latest quarter · SG&A
- $3.20B Jul 31, 2026
- Latest quarter · FMP standardized operating result
- $1.76B Jul 31, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 31, 2026 | $9.76B | $771.00M | $3.20B | $1.76B |
| Apr 24, 2026 | $9.81B | $671.00M | $3.06B | $1.56B |
| Jan 23, 2026 | $9.02B | $722.00M | $2.96B | $1.77B |
| Oct 24, 2025 | $8.96B | $754.00M | $2.97B | $1.69B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $9.76B Sep 1, 2026
- Latest report · revenue estimate
- $9.55B Sep 1, 2026
- Latest report · revenue vs estimate
- Above estimate Sep 1, 2026
- Latest report · EPS vs estimate
- Above estimate Sep 1, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Sep 1, 2026 | $9.76B | $9.55B | $1.4500 | $1.3900 |
| Jun 3, 2026 | $9.81B | $9.62B | $1.5500 | $1.5400 |
| Feb 17, 2026 | $9.02B | $8.91B | $1.3600 | $1.3400 |
| Nov 18, 2025 | $8.96B | $8.87B | $1.3600 | $1.3100 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $9.76B | $1.47B | $1.14 (diluted) |
| Q4 FY2026 | $9.81B | $1.24B | $0.96 (diluted) |
| Q3 FY2026 | $9.02B | $1.14B | $0.89 (diluted) |
| Q2 FY2026 | $8.96B | $1.37B | $1.07 (diluted) |
What are the financial strengths and risks for Medtronic (MDT)?
Short answer
Cash and short-term investments were $8.82B at the Jul 31, 2026 balance-sheet date. Operating cash flow was $1.79B for the quarter ended Jul 31, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Liquidity is substantial and near-term coverage ratios are comfortable, but cash and investments do not offset total debt. The balance sheet is therefore liquid rather than debt-free, with a meaningful net debt position despite a cash balance that remains above much of its recent range.
Operating cash flow has remained positive, and capital spending has consumed a minority of that inflow in every displayed period. Cash conversion is uneven across quarters, however, so a strong period should not be treated as the normal run rate.
The operating risk is visible in the latest cost structure: stable sequential revenue coincided with lower gross profit and higher selling and administrative expense. If that combination persists, it would work directly against management’s leverage objective; weakness in cardiovascular procedures would matter especially because that portfolio supplies the largest segment contribution.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $1.79B Jul 31, 2026
- Previous quarter · operating cash flow
- $2.57B Apr 24, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jul 31, 2026 | $1.79B | −$503.00M |
| Apr 24, 2026 | $2.57B | −$488.00M |
| Jan 23, 2026 | $2.74B | −$444.00M |
| Oct 24, 2025 | $925.00M | −$468.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Medtronic (MDT)?
Short answer · as of
The next earnings report is expected on Nov 17, 2026.
Research dated 2026-09-12.
The next results should be read through gross profit and operating expense behavior, not merely the adjusted earnings comparison. Revenue holding near its recent level would carry more weight if operating profit expands without another sequential gross-profit setback or disproportionate growth in selling and administrative costs.
Cash conversion deserves a separate check. Operating cash flow has varied sharply despite steadier capital spending, while cash and short-term investments slipped from the latest peak and debt remains far larger than liquid resources.
Longer-range consensus embeds continued revenue and earnings expansion. Evidence for that path would be broader segment growth accompanied by rising operating profit and cash flow, especially if cardiovascular remains the main contributor and diabetes adds recurring pump and monitoring demand.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Taken together, we expect fiscal year '27 operating profit to grow approximately 10%, with operating margin expanding approximately 50 basis points year-over-year.
Thierry Pieton ·
And on the full year, we're going to deliver a leverage P&L.
Thierry Pieton ·
How does Medtronic compare with its peers?
Short answer
Medtronic's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Medtronic differs from a narrowly focused device maker because its revenue spans implantable cardiac therapies, surgical tools and platforms, neuroscience systems, patient monitoring, and diabetes devices with associated consumables. The portfolio mixes procedure-linked products, durable clinical systems, software-enabled monitoring, and repeat-use supplies rather than relying on a uniform purchasing pattern.
Cardiovascular remains the economic anchor, but neuroscience and medical surgical also carry material scale, while diabetes contributes a smaller and more recurring product relationship. That breadth reduces dependence on a narrowly defined therapy while making consolidated margins sensitive to portfolio mix and spending across several development programs.
Established profitability, positive free cash generation, and sustained research spending characterize Medtronic more accurately than a high-growth device profile. Its relevant comparison is therefore with diversified medical-technology platforms whose value depends on steady clinical adoption and operating discipline across mature and developing franchises.
| Company | Price | Market value | Score |
|---|---|---|---|
| $504.73 Oct 2, 2026 | $128B | 97 5-pillar Oct 4, 2026 | |
| $85.36 Oct 2, 2026 | $32.2B | 96 5-pillar Oct 4, 2026 | |
| $317.55 Oct 2, 2026 | $12.5B | 95 5-pillar Oct 4, 2026 | |
| $61.15 Oct 2, 2026 | $125B | 91 5-pillar Oct 4, 2026 | |
| $85.15 Oct 2, 2026 | $49.0B | 90 5-pillar Oct 4, 2026 | |
| $47.03 Oct 2, 2026 | $94.2B | 88 5-pillar Oct 4, 2026 | |
| $208.54 Oct 2, 2026 | $20.3B | 87 5-pillar Oct 4, 2026 | |
| $26.42 Oct 2, 2026 | $11.1B | 87 5-pillar Oct 4, 2026 | |
| $42.60 Oct 2, 2026 | $63.3B | 84 5-pillar Oct 4, 2026 | |
| $39.92 Oct 2, 2026 | $95.9B | 83 5-pillar Oct 4, 2026 | |
| Medtronic (MDT) — this page | $86.38 | $111B | 80 |
| $88.29 Oct 2, 2026 | $17.1B | 80 5-pillar Oct 4, 2026 | |
| $275.43 Oct 2, 2026 | $106B | 79 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $83.00 – $115.00
- Consensus target
- $98.00
- Median target
- $98.00
Consensus record · Captured .
Measured against a quoted price of $86.38 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 16, 2026
- Transactions
- 46
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 4
- Other transactions
- 42
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 86.1% Period end Jun 30, 2026
- Previous quarter · ownership
- 85.4% Prior to period end Jun 30, 2026
- Reporting holders
- 2,206 Period end Jun 30, 2026
- Previous quarter · holders
- 2,313 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 114,020,787 |
| Vanguard Capital Management LLC | 83,816,735 |
| State Street Corp | 63,399,315 |
| Vanguard Portfolio Management LLC | 34,059,967 |
| Geode Capital Management, LLC | 30,192,015 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Medtronic (MDT)?
Medtronic Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What makes Medtronic more than a pacemaker company?
Pacemakers sit inside a much broader cardiovascular franchise, while surgical instruments, robotic and imaging systems, neuroscience therapies, ventilation, patient monitoring, insulin pumps, glucose monitoring, and recurring consumables extend the business across many clinical workflows.
Why is Medtronic’s Diabetes unit economically different from its surgical businesses?
Diabetes combines pumps and smart delivery hardware with glucose monitoring and associated consumables, creating an ongoing patient-product relationship. Medical surgical is more directly connected to instruments, platforms, monitoring equipment, and therapies used around clinical procedures.
Can Medtronic deliver the operating leverage management described?
Recent operating profit moved favorably, but the latest sequential decline in gross profit and rise in selling and administrative expense set a demanding test. Leverage becomes visible when operating profit and cash flow advance with revenue rather than depending only on adjusted earnings performance.
How should investors read Medtronic’s repeated adjusted earnings beats?
The pattern shows consistent delivery relative to consensus, but it does not settle the quality of the underlying improvement. Gross profit, operating profit, and operating cash flow reveal whether those beats are accompanied by stronger business economics.
What is the MDT stock price today?
The last price recorded on this page for Medtronic plc (MDT) is $86.38, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MDT price target?
The analyst consensus price target for Medtronic plc (MDT) is $98.00 (range $83.00 to $115.00, median $98.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does MDT pay a dividend?
Yes. Medtronic plc (MDT) shows a trailing 12-month dividend yield of 3.31%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (85 figures)
The 85 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Thierry Pieton (Sep 1, 2026): Taken together, we expect fiscal year '27 operating profit to grow approximately 10%, with operating margin expanding approximately 50 basis points year-over-year. Thierry Pieton (Sep 1, 2026): And on the full year, we're going to deliver a leverage P&L. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Building TWO Parkmore Business Park West, Galway, H91 4K49 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Building Two, Parkmore Business Park West, Galway, GA, H91 4K49, IE". The FMP company description names Dublin, Ireland as the headquarters; this page uses the address in this row. |
FMP — 74 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 17, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $86.38 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T18:04:29.351Z. | |
px.change | Change on the day | -0.07% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $111B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:02.000Z. Captured from FMP at 2026-10-04T18:04:26.426Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.06 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q1 FY2027 | $9.76B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $73.31–$106.33 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 21.14 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 34.60M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.57 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Geoffrey Straub Martha | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 95,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2022 through FY2026: FY2022 revenue $31.69B, net result $5.04B; FY2023 revenue $31.23B, net result $3.76B; FY2024 revenue $32.36B, net result $3.68B; FY2025 revenue $33.54B, net result $4.66B; FY2026 revenue $36.36B, net result $4.80B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Diabetes Group $3.11B · Medical Surgical $8.81B · Neuroscience Group $10.29B · Cardiac and Vascular Group $13.98B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 66.7% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-07-31.revenue_k | Revenue — period end 2026-07-31 | $9.76B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-31.rd_k | R&D — period end 2026-07-31 | $771.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-31.sga_k | SG&A — period end 2026-07-31 | $3.20B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-31.operating_result_k | FMP standardized operating result — period end 2026-07-31 | $1.76B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-24.revenue_k | Revenue — period end 2026-04-24 | $9.81B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-24.rd_k | R&D — period end 2026-04-24 | $671.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-24.sga_k | SG&A — period end 2026-04-24 | $3.06B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-24.operating_result_k | FMP standardized operating result — period end 2026-04-24 | $1.56B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-23.revenue_k | Revenue — period end 2026-01-23 | $9.02B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-23.rd_k | R&D — period end 2026-01-23 | $722.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-23.sga_k | SG&A — period end 2026-01-23 | $2.96B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-23.operating_result_k | FMP standardized operating result — period end 2026-01-23 | $1.77B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-24.revenue_k | Revenue — period end 2025-10-24 | $8.96B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-24.rd_k | R&D — period end 2025-10-24 | $754.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-24.sga_k | SG&A — period end 2025-10-24 | $2.97B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-24.operating_result_k | FMP standardized operating result — period end 2025-10-24 | $1.69B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-09-01.revenue_actual | Revenue · reported — report date 2026-09-01 | $9.76B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-01.revenue_estimated | Revenue · estimate — report date 2026-09-01 | $9.55B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-01.eps_actual | EPS · reported — report date 2026-09-01 | $1.4500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-01.eps_estimated | EPS · estimate — report date 2026-09-01 | $1.3900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-03.revenue_actual | Revenue · reported — report date 2026-06-03 | $9.81B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-03.revenue_estimated | Revenue · estimate — report date 2026-06-03 | $9.62B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-03.eps_actual | EPS · reported — report date 2026-06-03 | $1.5500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-03.eps_estimated | EPS · estimate — report date 2026-06-03 | $1.5400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.revenue_actual | Revenue · reported — report date 2026-02-17 | $9.02B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.revenue_estimated | Revenue · estimate — report date 2026-02-17 | $8.91B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_actual | EPS · reported — report date 2026-02-17 | $1.3600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_estimated | EPS · estimate — report date 2026-02-17 | $1.3400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-18.revenue_actual | Revenue · reported — report date 2025-11-18 | $8.96B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-18.revenue_estimated | Revenue · estimate — report date 2025-11-18 | $8.87B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-18.eps_actual | EPS · reported — report date 2025-11-18 | $1.3600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-18.eps_estimated | EPS · estimate — report date 2025-11-18 | $1.3100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2027 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $8.82B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $1.79B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-07-31. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $1.31B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $28.15B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 2.20× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-07-31.operating_cash_flow_m | Operating cash flow — period end 2026-07-31 | $1.79B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-24.operating_cash_flow_m | Operating cash flow — period end 2026-04-24 | $2.57B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-07-31.capex_m | Capital expenditure (reported) — period end 2026-07-31 | −$503.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-24.capex_m | Capital expenditure (reported) — period end 2026-04-24 | −$488.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-01-23.operating_cash_flow_m | Operating cash flow — period end 2026-01-23 | $2.74B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-01-23.capex_m | Capital expenditure (reported) — period end 2026-01-23 | −$444.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-10-24.operating_cash_flow_m | Operating cash flow — period end 2025-10-24 | $925.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-10-24.capex_m | Capital expenditure (reported) — period end 2025-10-24 | −$468.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $83.00 – $115.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $98.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $98.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 46 transactions · 0 purchases, 4 sales, 42 other transactions · 8 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 16, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 86.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 85.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 2,206 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 2,313 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 114,020,787 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 83,816,735 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | State Street Corp — shares in provider snapshot | 63,399,315 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 34,059,967 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Geode Capital Management, LLC — shares in provider snapshot | 30,192,015 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.88 · Piotroski F 9 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 12.59× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $8.82B at Jul 31, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-07-31. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $2.86 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 3.31% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-09-01.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($9.76B) with the recorded estimate ($9.55B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-09-01.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.4500) with the recorded estimate ($1.3900) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 80 of 100 · Exceptional · pillars 86 / 53 / 66 / 81 / 68 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 80 (stored snapshot Oct 3, 2026) → 80 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-07-31. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-07-31.revenue_k,fin.q_table.depth.2026-07-31.rd_k,fin.q_table.depth.2026-07-31.sga_k,fin.q_table.depth.2026-07-31.operating_result_k,fin.q_table.depth.2026-04-24.revenue_k,fin.q_table.depth.2026-04-24.rd_k,fin.q_table.depth.2026-04-24.sga_k,fin.q_table.depth.2026-04-24.operating_result_k,fin.q_table.depth.2026-01-23.revenue_k,fin.q_table.depth.2026-01-23.rd_k,fin.q_table.depth.2026-01-23.sga_k,fin.q_table.depth.2026-01-23.operating_result_k,fin.q_table.depth.2025-10-24.revenue_k,fin.q_table.depth.2025-10-24.rd_k,fin.q_table.depth.2025-10-24.sga_k,fin.q_table.depth.2025-10-24.operating_result_k. - Earnings-history note. Source series as of 2026-09-01. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-09-01.revenue_actual,earn.history.depth.2026-09-01.revenue_estimated,earn.history.depth.2026-09-01.revenue_actual.comparison,earn.history.depth.2026-09-01.eps_actual.comparison,earn.history.depth.2026-09-01.eps_actual,earn.history.depth.2026-09-01.eps_estimated,earn.history.depth.2026-06-03.revenue_actual,earn.history.depth.2026-06-03.revenue_estimated,earn.history.depth.2026-06-03.eps_actual,earn.history.depth.2026-06-03.eps_estimated,earn.history.depth.2026-02-17.revenue_actual,earn.history.depth.2026-02-17.revenue_estimated,earn.history.depth.2026-02-17.eps_actual,earn.history.depth.2026-02-17.eps_estimated,earn.history.depth.2025-11-18.revenue_actual,earn.history.depth.2025-11-18.revenue_estimated,earn.history.depth.2025-11-18.eps_actual,earn.history.depth.2025-11-18.eps_estimated. - Cash-flow note. Source series as of 2026-07-31. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-07-31.operating_cash_flow_m,fin.opcf.depth.2026-04-24.operating_cash_flow_m,fin.opcf.depth.2026-07-31.capex_m,fin.opcf.depth.2026-04-24.capex_m,fin.opcf.depth.2026-01-23.operating_cash_flow_m,fin.opcf.depth.2026-01-23.capex_m,fin.opcf.depth.2025-10-24.operating_cash_flow_m,fin.opcf.depth.2025-10-24.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Diabetes Group: $3.11B; Medical Surgical: $8.81B; Neuroscience Group: $10.29B; Cardiac and Vascular Group: $13.98B | 2026-04-24 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2026-04-24 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-09-01 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Legal name | Medtronic plc | 2026-06-18 | OFFICIAL | SEC EDGAR — 10-K filed 2026-06-18 |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Devices The company's SEC filings classify it under SIC 3845 — Electromedical & Electrotherapeutic Apparatus. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-09-01 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash, investments and debt | Total debt: $28.15B; Liquidity basis: cash and short-term investments; Total liabilities: $42.46B; Cash and short-term investments: $8.82B; Cash and investments: $10.13B; Long-term investments: $1.31B; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $10.13B; Cash and short-term investments: $8.82B; Long-term investments: $1.31B; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-07-31 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-07-31; Cash basis: cash and short-term investments; Net cash: -$19.33B; Total debt: $28.15B; Cash and investments: $8.82B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-07-31 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 2.09; Current ratio: 2.07; Debt to equity: 0.56; Net margin: 13.9%; Gross margin: 66.7%; Operating margin: 18.1%; Return on assets: 5.6%; Return on equity: 10.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 2.98; Piotroski F-score: 9 Altman Z below 1.8 is the conventional distress zone. For a company holding large cash against negative retained earnings the score mostly reflects the retained-earnings term. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-11-17; EPS estimate: $1.34 per share; Revenue estimate: $9.48B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.
ETFs that hold MDT
Funds in our ETF coverage that list MDT among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| WisdomTree U.S. AI Enhanced Value Fund (AIVL) | 3.15% | |
| Eventide High Dividend ETF (ELCV) | 3.11% |